In March 2025, a child with a rare disease died of thrombotic microangiopathy within a week of receiving customized gene editing treatment at Shanghai Xinhua Hospital. On November 13, Shanghai authorities reported: the research team failed to timely disclose safety warnings from animal trials, the published paper did not report the child's death, ethical reviews were lax, and some personnel accepted approximately 1.06 million yuan in bribes from the family. Two responsible individuals have been dismissed and disqualified from research awards for five years.